Osteoporosis Treatment Market Size and Share Outlook 2031
The osteoporosis treatment market size is projected to surge from US$ 16.83 billion in 2023 to US$ 22.72 billion by 2031; the market is estimated to record a CAGR of 3.8% during 2023–2031.
Analyst Perspective:
The report includes growth prospects owing to the current osteoporosis treatment market trends and their foreseeable impact during the forecast period. Osteoporosis can cause bones to become brittle to an extent that a minor fall can result in fractures, thereby affecting the quality of life. Early detection and treatment help in slowing or even stopping the progression of osteoporosis, in turn, reducing the risk of fractures. Thus, the prevalence of osteoporosis increases the need for diagnosis, which subsequently boosts the growth of the osteoporosis treatment market. Osteoporosis is mainly observed in women due to hormonal changes at menopause that affect the bone density. Apart from hormonal changes, other factors that increase the risk of osteoporosis in aging individuals are rheumatoid arthritis, a family history of osteoporosis, and long-term use of medications that affect bone strength. According to the International Osteoporosis Foundation, of the majority of people who have osteoporosis, 25% are women and 5% are men aged over 65.
Market Overview:
Osteoporosis is a progressive disease associated with high-risk fractures in men, postmenopausal women, and the geriatric population. Osteoporosis patients are particularly prone to bone, hip, forearm, spine, and wrist fractures. Therefore, it is described as a metabolic disease that lowers bone mineral density and leads to bone fractures. The therapeutic arsenal often includes bisphosphonates, hormone therapy, denosumab, and a range of nutritional supplements recommended along with lifestyle adjustments such as increased physical activity and a calcium-rich diet. Key factors driving the osteoporosis treatment market growth include an increase in healthcare spending on discovery and drug development and increasing awareness about available drugs for the treatment of osteoporosis.
Customize Research To Suit Your Requirement
We can optimize and tailor the analysis and scope which is unmet through our standard offerings. This flexibility will help you gain the exact information needed for your business planning and decision making.
Osteoporosis Treatment Market: Strategic Insights
Mrinal
Have a question?
Mrinal will walk you through a 15-minute call to present the report’s content and answer all queries if you have any.
Speak to Analyst
Customize Research To Suit Your Requirement
We can optimize and tailor the analysis and scope which is unmet through our standard offerings. This flexibility will help you gain the exact information needed for your business planning and decision making.
Osteoporosis Treatment Market: Strategic Insights
Mrinal
Have a question?
Mrinal will walk you through a 15-minute call to present the report’s content and answer all queries if you have any.
Speak to Analyst
Market Driver:
Increasing Cases of Osteoporosis and Modifications in Lifestyle Propel Market Growth
The prevalence of osteoporosis is increasing worldwide, largely due to improper lifestyle, poor diet, lack of exercise, inadequate calcium and vitamin D intake, and hormonal imbalance. As per the International Osteoporosis Foundation, more than 8.9 million fractures are caused because of osteoporosis annually, resulting in one osteoporotic fracture every three seconds, and it is estimated that it affects 200 million women worldwide. The increasing geriatric population is also an important factor driving the osteoporosis treatment market growth. According to a study published in Labiotech, "Advancements in Osteoporosis Research," about 10 million Americans have osteoporosis. ~44 million people have low bone density, putting them at an increased risk of osteoporosis. The risk of developing osteoporosis significantly increases with age; it is estimated that adults aged 50 and above are at high risk of fracture. Three-quarters of adults aged 65 and older suffering from hip fractures annually in the US are women, and it is estimated that around 15–36% of hip fracture patients die within a year. A broader emphasis on holistic health and wellness encourages the adoption of regular health screenings, including bone density scans. As individuals proactively monitor their bone health, early diagnosis and interventions are becoming increasingly important, further stimulating the expansion of the market. The osteoporosis treatment market is receiving significant impetus from increasing awareness about bone health, which drives the demand for preventive and therapeutic solutions.
Segmental Analysis:
The osteoporosis treatment market analysis has been carried out by considering the following segments: drug class, type, route of administration, and distribution channel.
Based on drug class, the osteoporosis treatment market is segmented into RANKL, bisphosphonates, selective estrogen receptor modulators (SERM), hormone therapies, and others. The RANKL segment held the largest market share in 2023. However, the hormone therapies segment is estimated to register the highest CAGR during 2023–2031. The bisphosphonates segment also holds a considerable share in the osteoporosis treatment market. Bisphosphonates, which include compounds such as alendronate and zoledronic acid, have proven to be effective in inhibiting bone resorption, increasing bone density, and minimizing the risk of fractures. Their extensive clinical history, regulatory approvals, and availability of oral and intravenous formulations make them the preferred choice by healthcare professionals. Furthermore, their cost-effectiveness and comprehensive insurance coverage contribute to their wide adoption in the osteoporosis treatment market.
The market, based on type, is bifurcated into primary osteoporosis and secondary osteoporosis. The primary osteoporosis segment held a larger osteoporosis treatment market share in 2023. Primary osteoporosis occurs with aging, which results in slow bone renewal. According to a study published in the National Library of Medicine titled “Prevalence of Primary Osteoporosis and Low Bone Mass in Postmenopausal Women and Associated Risk Factors,” 30% of women aged over 50 have osteoporosis worldwide. 8–9% of bone fractures per year are known to be caused by osteoporosis. In addition, men and women aged 70 years and above experience an imbalance between bone formation and loss, leading to back pain, reduced quality of life, and impairment of daily activities.
Based on the route of administration, the osteoporosis treatment market is bifurcated into oral and injectable. The injectable segment held the largest osteoporosis treatment market share in 2023. The injectable segment is anticipated to register the highest CAGR during 2023–2031. The dominant presence of the injectable segment in the market can be attributed to its effectiveness and reliability as a drug delivery method. Administering treatment through injections ensures direct entry of the drug into the bloodstream, resulting in rapid and predictable absorption, which is a key advantage in the treatment of osteoporosis. Additionally, certain osteoporosis medications are available only in injectable form, further promoting its market share. With improving patient compliance for self-administered injections and the continued development of innovative drug delivery solutions, the injectable segment is poised to maintain its strong market position.
Regional Analysis:
The scope of the osteoporosis treatment market report includes North America, Europe, Asia Pacific, the Middle East & Africa, and South & Central America. The market in North America was valued at US$ 8.26 billion in 2023 and is projected to reach US$ 11.26 billion by 2031; it is expected to register a CAGR of 3.9% during 2023–2031. One of the key factors driving the market growth in this region is the significant aging population in the region, with greater awareness of osteoporosis. Second, advanced healthcare infrastructure and comprehensive access to medical services enable timely diagnosis and treatment. In addition, the presence of large pharmaceutical companies and ongoing research and development initiatives are encouraging the introduction of innovative therapies. Finally, favorable reimbursement policies and insurance coverage support patients seeking osteoporosis treatment, promoting the osteoporosis treatment market in North America.
The Asia Pacific osteoporosis treatment market is expected to record the highest CAGR of 4.7%. The region, especially with countries such as India and China, is home to a sizable pharmaceutical industry. China is a pharmaceutical manufacturing hub. The projected market growth in this region is attributed to the growing middle class and increased accessibility to healthcare. Additionally, improvements in healthcare infrastructure and the emerging pharmaceutical sector make the Asia Pacific a hub for the significant growth and development of the osteoporosis treatment market.
Osteoporosis Treatment Market Report Scope
Key Player Analysis:
Pfizer Inc.; Amgen Inc.; Cadila Pharmaceuticals; Eli Lilly and Company; Daiichi Sankyo Company, Limited; Teva Pharmaceuticals Inc.; Asahi Kasei Corporation; Novartis AG; Chugai Pharmaceutical Co., Ltd.; and Teijin Pharma Limited are among the key players profiled in the osteoporosis treatment market report.
Recent Developments:
Companies operating in the osteoporosis treatment market adopt mergers and acquisitions as key growth strategies. As per company press releases, a few recent market developments are listed below:
- In October 2021, Entera Bio, a leading biotechnology company, released key data for its mid-stage oral osteoporosis drug formulation study. The company has advanced Phase 3 registration of this study.
- In August 2021, the Drug Controller General of India (DCGI) gave Marketing Authorization (MA) to Enzene Biosciences Ltd, for its biosimilar drug Denosumab, which is indicated for treating osteoporosis in adults.
- In January 2021, Theramex, a pharmaceutical company headquartered in London, launched the osteoporosis drug Livogiva in Europe.
Report Coverage
Revenue forecast, Company Analysis, Industry landscape, Growth factors, and Trends
Segment Covered
This text is related
to segments covered.
Regional Scope
North America, Europe, Asia Pacific, Middle East & Africa, South & Central America
Country Scope
This text is related
to country scope.
Frequently Asked Questions
The factors driving the growth of the osteoporosis treatment market include the increasing cases of osteoporosis due to modifications in lifestyle and growing awareness and diagnosis of osteoporosis.
The osteoporosis treatment market is expected to be valued at US$ 22.72 billion in 2031.
The osteoporosis treatment market majorly consists of the players such as Pfizer Inc.; Amgen Inc.; Cadila Pharmaceuticals; Eli Lilly and Company; Daiichi Sankyo Company, Limited; Teva Pharmaceuticals Inc.; Asahi Kasei Corporation; Novartis AG; Chugai Pharmaceutical Co., Ltd.; and Teijin Pharma Limited.
The osteoporosis treatment includes various drugs and therapeutic modalities carefully developed to combat osteoporosis, a disease characterized by bones becoming brittle and prone to fractures. As osteoporosis is a progressive disease, initiating the treatment at an early stage can yield better results. Osteoporosis treatment involves a series of bone density tests to determine the mineral proportion in the bones. Depending on the severity of cases, osteoporosis treatment is suggested to help reduce pain, improve mobility, and reduce the risk of disability.
The osteoporosis treatment market was valued at US$ 16.83 billion in 2023.
The global osteoporosis treatment market, Based on drug class, the osteoporosis treatment market is segmented into RANKL, bisphosphonates, selective estrogen receptor modulators (SERM), hormone therapies, and others. The RANKL segment held the largest osteoporosis treatment market share in 2023. However, the hormone therapies segment is predicted to register the highest CAGR during 2021–2031. Based on type, is bifurcated into primary osteoporosis and secondary osteoporosis. The primary osteoporosis segment held a larger market share in 2023 and is estimated to record a faster CAGR during 2023–2031. Based on end user, the market is segmented into hospital pharmacies, retail pharmacies, and online pharmacies. The hospital pharmacies segment held the largest osteoporosis treatment market share in 2023 and is estimated to register the highest CAGR during the forecasted period.
1. Introduction
1.1 Scope of the Study
1.2 Market Definition, Assumptions and Limitations
1.3 Market Segmentation
2. Executive Summary
2.1 Key Insights
2.2 Market Attractiveness Analysis
3. Research Methodology
4. Osteoporosis Treatment Market Landscape
4.1 Overview
4.2 PEST Analysis
4.3 Ecosystem Analysis
4.3.1 List of Vendors in the Value Chain
5. Osteoporosis Treatment Market - Key Market Dynamics
5.1 Key Market Drivers
5.2 Key Market Restraints
5.3 Key Market Opportunities
5.4 Future Trends
5.5 Impact Analysis of Drivers and Restraints
6. Osteoporosis Treatment Market - Global Market Analysis
6.1 Osteoporosis Treatment - Global Market Overview
6.2 Osteoporosis Treatment - Global Market and Forecast to 2031
7. Osteoporosis Treatment Market – Revenue Analysis (USD Million) – By Drug Type, 2021-2031
7.1 Overview
7.2 Rank Ligand (RANKL) Inhibitor
7.3 Bisphosphonates
7.4 Hormone
7.5 Selective Estrogen Receptor Modulators (SERMs)
7.6 Others
8. Osteoporosis Treatment Market – Revenue Analysis (USD Million) – By Route of Administration, 2021-2031
8.1 Overview
8.2 Oral
8.3 Injectable
9. Osteoporosis Treatment Market – Revenue Analysis (USD Million) – By Type, 2021-2031
9.1 Overview
9.2 Primary Osteoporosis
9.3 Secondary Osteoporosis
10. Osteoporosis Treatment Market – Revenue Analysis (USD Million) – By Distribution Channel, 2021-2031
10.1 Overview
10.2 Hospitals
10.3 Retail Pharmacies
10.4 Online Pharmacies
11. Osteoporosis Treatment Market - Revenue Analysis (USD Million), 2021-2031 – Geographical Analysis
11.1 North America
11.1.1 North America Osteoporosis Treatment Market Overview
11.1.2 North America Osteoporosis Treatment Market Revenue and Forecasts to 2031
11.1.3 North America Osteoporosis Treatment Market Revenue and Forecasts and Analysis - By Drug Type
11.1.4 North America Osteoporosis Treatment Market Revenue and Forecasts and Analysis - By Route of Administration
11.1.5 North America Osteoporosis Treatment Market Revenue and Forecasts and Analysis - By Type
11.1.6 North America Osteoporosis Treatment Market Revenue and Forecasts and Analysis - By Distribution Channel
11.1.7 North America Osteoporosis Treatment Market Revenue and Forecasts and Analysis - By Countries
11.1.7.1 United States Osteoporosis Treatment Market
11.1.7.1.1 United States Osteoporosis Treatment Market, by Drug Type
11.1.7.1.2 United States Osteoporosis Treatment Market, by Route of Administration
11.1.7.1.3 United States Osteoporosis Treatment Market, by Type
11.1.7.1.4 United States Osteoporosis Treatment Market, by Distribution Channel
11.1.7.2 Canada Osteoporosis Treatment Market
11.1.7.2.1 Canada Osteoporosis Treatment Market, by Drug Type
11.1.7.2.2 Canada Osteoporosis Treatment Market, by Route of Administration
11.1.7.2.3 Canada Osteoporosis Treatment Market, by Type
11.1.7.2.4 Canada Osteoporosis Treatment Market, by Distribution Channel
11.1.7.3 Mexico Osteoporosis Treatment Market
11.1.7.3.1 Mexico Osteoporosis Treatment Market, by Drug Type
11.1.7.3.2 Mexico Osteoporosis Treatment Market, by Route of Administration
11.1.7.3.3 Mexico Osteoporosis Treatment Market, by Type
11.1.7.3.4 Mexico Osteoporosis Treatment Market, by Distribution Channel
Note - Similar analysis would be provided for below mentioned regions/countries
11.2 Europe
11.2.1 Germany
11.2.2 France
11.2.3 Italy
11.2.4 Spain
11.2.5 United Kingdom
11.2.6 Rest of Europe
11.3 Asia-Pacific
11.3.1 Australia
11.3.2 China
11.3.3 India
11.3.4 Japan
11.3.5 South Korea
11.3.6 Rest of Asia-Pacific
11.4 Middle East and Africa
11.4.1 South Africa
11.4.2 Saudi Arabia
11.4.3 U.A.E
11.4.4 Rest of Middle East and Africa
11.5 South and Central America
11.5.1 Brazil
11.5.2 Argentina
11.5.3 Rest of South and Central America
12. Industry Landscape
12.1 Mergers and Acquisitions
12.2 Agreements, Collaborations, Joint Ventures
12.3 New Product Launches
12.4 Expansions and Other Strategic Developments
13. Competitive Landscape
13.1 Heat Map Analysis by Key Players
13.2 Company Positioning and Concentration
14. Osteoporosis Treatment Market - Key Company Profiles
14.1 Teva Pharmaceutical Industries Ltd.
14.1.1 Key Facts
14.1.2 Business Description
14.1.3 Products and Services
14.1.4 Financial Overview
14.1.5 SWOT Analysis
14.1.6 Key Developments
Note - Similar information would be provided for below list of companies
14.2 Pfizer Inc.
14.3 Amgen Inc.
14.4 Cadila Pharmaceuticals
14.5 Daiichi Sankyo Company, Limited
14.6 Chugai Pharmaceuticals Co. Ltd.
14.7 Teijin Pharma Limited
14.8 Novartis AG
14.9 Eli Lily and Company
14.10 Asahi Kasei Pharma Corporation
15. Appendix
15.1 Glossary
15.2 About The Insight Partners
15.3 Market Intelligence Cloud
The List of Companies - Osteoporosis Treatment Market
- Pfizer Inc.
- Amgen Inc.
- Cadila Pharmaceuticals
- Eli Lilly and Company
- Daiichi Sankyo Company, Limited
- Teva Pharmaceuticals Inc.
- Asahi Kasei Corporation
- Novartis AG
- Chugai Pharmaceutical Co., Ltd.
- Teijin Pharma Limited
The Insight Partners performs research in 4 major stages: Data Collection & Secondary Research, Primary Research, Data Analysis and Data Triangulation & Final Review.
- Data Collection and Secondary Research:
As a market research and consulting firm operating from a decade, we have published many reports and advised several clients across the globe. First step for any study will start with an assessment of currently available data and insights from existing reports. Further, historical and current market information is collected from Investor Presentations, Annual Reports, SEC Filings, etc., and other information related to company’s performance and market positioning are gathered from Paid Databases (Factiva, Hoovers, and Reuters) and various other publications available in public domain.
Several associations trade associates, technical forums, institutes, societies and organizations are accessed to gain technical as well as market related insights through their publications such as research papers, blogs and press releases related to the studies are referred to get cues about the market. Further, white papers, journals, magazines, and other news articles published in the last 3 years are scrutinized and analyzed to understand the current market trends.
- Primary Research:
The primarily interview analysis comprise of data obtained from industry participants interview and answers to survey questions gathered by in-house primary team.
For primary research, interviews are conducted with industry experts/CEOs/Marketing Managers/Sales Managers/VPs/Subject Matter Experts from both demand and supply side to get a 360-degree view of the market. The primary team conducts several interviews based on the complexity of the markets to understand the various market trends and dynamics which makes research more credible and precise.
A typical research interview fulfils the following functions:
- Provides first-hand information on the market size, market trends, growth trends, competitive landscape, and outlook
- Validates and strengthens in-house secondary research findings
- Develops the analysis team’s expertise and market understanding
Primary research involves email interactions and telephone interviews for each market, category, segment, and sub-segment across geographies. The participants who typically take part in such a process include, but are not limited to:
- Industry participants: VPs, business development managers, market intelligence managers and national sales managers
- Outside experts: Valuation experts, research analysts and key opinion leaders specializing in the electronics and semiconductor industry.
Below is the breakup of our primary respondents by company, designation, and region:
Once we receive the confirmation from primary research sources or primary respondents, we finalize the base year market estimation and forecast the data as per the macroeconomic and microeconomic factors assessed during data collection.
- Data Analysis:
Once data is validated through both secondary as well as primary respondents, we finalize the market estimations by hypothesis formulation and factor analysis at regional and country level.
- 3.1 Macro-Economic Factor Analysis:
We analyse macroeconomic indicators such the gross domestic product (GDP), increase in the demand for goods and services across industries, technological advancement, regional economic growth, governmental policies, the influence of COVID-19, PEST analysis, and other aspects. This analysis aids in setting benchmarks for various nations/regions and approximating market splits. Additionally, the general trend of the aforementioned components aid in determining the market's development possibilities.
- 3.2 Country Level Data:
Various factors that are especially aligned to the country are taken into account to determine the market size for a certain area and country, including the presence of vendors, such as headquarters and offices, the country's GDP, demand patterns, and industry growth. To comprehend the market dynamics for the nation, a number of growth variables, inhibitors, application areas, and current market trends are researched. The aforementioned elements aid in determining the country's overall market's growth potential.
- 3.3 Company Profile:
The “Table of Contents” is formulated by listing and analyzing more than 25 - 30 companies operating in the market ecosystem across geographies. However, we profile only 10 companies as a standard practice in our syndicate reports. These 10 companies comprise leading, emerging, and regional players. Nonetheless, our analysis is not restricted to the 10 listed companies, we also analyze other companies present in the market to develop a holistic view and understand the prevailing trends. The “Company Profiles” section in the report covers key facts, business description, products & services, financial information, SWOT analysis, and key developments. The financial information presented is extracted from the annual reports and official documents of the publicly listed companies. Upon collecting the information for the sections of respective companies, we verify them via various primary sources and then compile the data in respective company profiles. The company level information helps us in deriving the base number as well as in forecasting the market size.
- 3.4 Developing Base Number:
Aggregation of sales statistics (2020-2022) and macro-economic factor, and other secondary and primary research insights are utilized to arrive at base number and related market shares for 2022. The data gaps are identified in this step and relevant market data is analyzed, collected from paid primary interviews or databases. On finalizing the base year market size, forecasts are developed on the basis of macro-economic, industry and market growth factors and company level analysis.
- Data Triangulation and Final Review:
The market findings and base year market size calculations are validated from supply as well as demand side. Demand side validations are based on macro-economic factor analysis and benchmarks for respective regions and countries. In case of supply side validations, revenues of major companies are estimated (in case not available) based on industry benchmark, approximate number of employees, product portfolio, and primary interviews revenues are gathered. Further revenue from target product/service segment is assessed to avoid overshooting of market statistics. In case of heavy deviations between supply and demand side values, all thes steps are repeated to achieve synchronization.
We follow an iterative model, wherein we share our research findings with Subject Matter Experts (SME’s) and Key Opinion Leaders (KOLs) until consensus view of the market is not formulated – this model negates any drastic deviation in the opinions of experts. Only validated and universally acceptable research findings are quoted in our reports.
We have important check points that we use to validate our research findings – which we call – data triangulation, where we validate the information, we generate from secondary sources with primary interviews and then we re-validate with our internal data bases and Subject matter experts. This comprehensive model enables us to deliver high quality, reliable data in shortest possible time.
Get Free Sample For